Nurix Therapeutics, Inc.
NRIX
$13.59
$0.403.03%
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -34.47% | -19.01% | -4.81% | 18.94% | 20.19% |
| Total Depreciation and Amortization | 23.45% | 23.42% | 22.11% | 23.04% | 27.54% |
| Total Amortization of Deferred Charges | -7.14% | 16.67% | 16.67% | 16.67% | 16.67% |
| Total Other Non-Cash Items | -20.31% | -21.08% | -14.29% | -9.68% | 0.14% |
| Change in Net Operating Assets | -191.45% | 198.40% | 176.63% | 199.47% | 205.78% |
| Cash from Operations | -112.11% | 33.47% | 36.44% | 54.80% | 49.09% |
| Capital Expenditure | -10.38% | -16.37% | -5.62% | 18.47% | 31.39% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -423.90% | -183.19% | -226.35% | 577.36% | 94.47% |
| Cash from Investing | -477.32% | -195.34% | -268.15% | 2,612.40% | 151.13% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 14,997.36% | 8,652.85% | 994.97% | -85.02% | -85.66% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 91.80% | -100.02% | -- | -- |
| Cash from Financing | 14,996.89% | 9,173.27% | 106.45% | -97.13% | -97.25% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 662.30% | 1,180.35% | 231.89% | 135.93% | 36.13% |
